Hypercholesteremia. Treatment with cholestyramine, a bile acid sequestering resin.
The results of administration of cholestyramine to 19 patients for periods of two to 21 months are reported. All patients consistently taking the drug obtained a significant reduction in the serum cholesterol. The average reduction was 26 per cent and the range was from 16 to 52 per cent. Cholestyramine acts as a bile acid sequestering resin, causing an increased loss of bile salts (cholates) in the stool. The drug acts by increasing the normal excretory pathway for cholesterol.
D000328:Adult; D000368:Aged; D002792:Cholestyramine Resin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D002792:Cholestyramine Resin